Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In an analysis, submitted as a pre-print prior to peer-review publication, a two-dose regimen of the ChAdOx1 nCoV-19 vaccine provides minimal protection against mild-moderate COVID-19 infection from the B.1.351 coronavirus variant first identified in South Africa.

Researcher working on vaccine in the lab

Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website.

Efficacy against severe COVID-19 infection from this variant was not assessed. The analyses being submitted in the pre-print show the vaccine had high efficacy against the original coronavirus strain in South Africa.

Researchers from the University of Witwatersrand and others in South Africa and the University of Oxford, UK found that viral neutralisation by sera induced by the ChAdOx1 nCoV-19 coronavirus vaccine against the B.1.351 coronavirus variant were substantially reduced when compared with the original strain of the coronavirus.

These early data, have been submitted for scientific peer-review, appear to confirm the theoretical observation that mutations in the virus seen in South Africa will allow ongoing transmission of the virus in vaccinated populations, as has been recently reported even in those with prior infection due to earlier circulating variants.

Read the full story on the University of Oxford website

Similar stories

Having a healthier heart associated with better problem-solving and reaction time

General Research

People with healthier heart structure and function appear to have better cognitive abilities, including increased capacity to solve logic problems and faster reaction times, according to a study involving University of Oxford and Queen Mary University of London (QMUL) researchers.

Eoghan Mulholland receives prestigious Lee Placito Research Fellowship

Awards and Appointments General

Dr Eoghan Mulholland has received the prestigious Lee Placito Research Fellowship in Gastrointestinal Cancer. Eoghan will use this 3-year position to research cell interactions in colorectal cancers.

Eleven Oxford professors honoured by the Academy of Medical Sciences

Awards and Appointments General

The Academy of Medical Sciences has elected 11 University of Oxford biomedical and health scientists to its fellowship.